Saturday 17 October 2026
Export PTGX’s income statement to Excel — free account
Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
128.75
7.80
−5.71%
Follow PTGX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 4 | 2 | 4 | 1 | — | — | — |
P/E ratio |
0.00 | 8.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
120.66 | 5.47 | 29.23 | 11.62 | 57.91 | 24.22 | 790.27 | 4.87 | 0.00 | — |
Altman Z-Score |
61.55 | 22.48 | 34.73 | 6.29 | 18.20 | 8.50 | (1.37) | 2.12 | 4.41 | — |
Altman Z″-Score (non-manufacturers) |
13.41 | 15.80 | 15.38 | 1.99 | 5.94 | 7.92 | (2.30) | 4.30 | 3.70 | — |
P/FCF ratio |
99.01 | 13.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.73 | — |
P/Operating CF |
(150.17) | (81.45) | 78.38 | (16.71) | (58.81) | (36.75) | (12.78) | (14.85) | (26.45) | — |
Beneish M-Score |
(7.18) | 29.24 | 405.14 | (3.84) | (3.31) | 106.46 | 151.71 | (1.24) | — | — |
P/B ratio |
9.03 | 3.52 | 3.95 | 2.45 | 5.28 | 2.48 | 2.28 | 1.34 | 3.10 | — |
Price to Tangible BV |
9.03 | 3.52 | 3.95 | 2.45 | 5.28 | 2.48 | 2.28 | 1.34 | 3.10 | — |
EV/Sales |
108.55 | 4.53 | 21.93 | 6.62 | 46.32 | 13.88 | 256.80 | 0.70 | 0.00 | — |
EV/EBITDA |
0.00 | 7.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
86.61 | 10.68 | (14.20) | (2.78) | (11.75) | (5.48) | (1.43) | (0.43) | 59.46 | — |
EV/FCF |
89.07 | 10.76 | (14.08) | (2.76) | (11.63) | (5.45) | (1.40) | (0.43) | 71.81 | — |
Quick Ratio |
12.49 | 12.32 | 16.53 | 7.61 | 7.46 | 7.66 | 3.95 | 5.10 | 3.43 | 12.41 |
Current Ratio |
12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 | 4.10 | 5.26 | 3.55 | 12.94 |
Net Debt/EBITDA |
3.49 | (1.70) | 3.60 | 1.85 | 2.70 | 4.95 | 1.57 | 3.10 | 3.91 | 2.41 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.32% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.07 | 0.79 | 0.20 | 0.09 | 0.08 | 0.12 | 0.00 | 0.20 | 0.16 | 0.00 |
Operating CF/Net income |
(0.44) | 0.67 | 0.89 | 0.85 | 0.86 | 1.10 | 0.54 | 1.28 | (0.10) | 0.79 |
Capex/Depreciation |
0.37 | 0.23 | 0.48 | (0.28) | (0.24) | (0.17) | (0.50) | (0.66) | (0.61) | (0.80) |
Interest Coverage |
— | — | — | (32.36) | (284.07) | (107.89) | (476.46) | (16.60) | (40.32) | (134.98) |
| (20.18%) | 54.39% | (28.59%) | (49.41%) | (43.32%) | (36.79%) | (80.20%) | (33.39%) | (35.50%) | (125.46%) | |
| (18.42%) | 49.91% | (26.06%) | (42.78%) | (37.36%) | (27.60%) | (52.44%) | (25.67%) | (28.68%) | (69.34%) | |
ROIC |
(208.75%) | 61.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (205.27%) |
Return on Tangible Assets |
(24.28%) | 50.27% | (23.53%) | (59.68%) | (42.06%) | (23.90%) | (69.17%) | (34.69%) | (33.82%) | (48.77%) |
Average Days of Receivables |
0.96 | 138.63 | 60.83 | 0.14 | 20.89 | 30.93 | 10,673.48 | 54.14 | 33.04 | 0.00 |
Research and Development Expense of Revenue |
346.16% | 31.80% | 200.27% | 474.83% | 460.60% | 260.26% | 28,139.83% | 192.39% | 230.18% | 0.00% |
Selling, General and Administrative Expense of Revenue |
97.47% | 10.00% | 55.82% | 119.40% | 99.41% | 65.10% | 6,817.75% | 44.29% | 58.71% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
99.91% | 8.64% | 48.82% | 91.05% | 59.93% | 27.59% | 3,616.02% | 22.37% | 21.14% | 0.00% |
Graham Net Nets |
0.09 | 0.22 | 0.25 | 0.40 | 0.19 | 0.39 | 0.39 | 0.73 | 0.29 | — |
Graham Number |
0.00 | 33.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(2.35%) | 11.61% | (6.32%) | (24.12%) | (7.89%) | (9.92%) | (42.55%) | (25.56%) | (10.26%) | — |
Free Cash Flow Yield |
1.01% | 7.69% | (5.33%) | (20.60%) | (6.88%) | (10.52%) | (23.28%) | (33.51%) | 0.86% | — |
Revenue per Share |
0.72 | 7.06 | 1.06 | 0.54 | 0.59 | 0.83 | 0.01 | 1.38 | 1.13 | 0.00 |
Operating CF per Share |
0.91 | 2.99 | (1.24) | (2.20) | (2.33) | (2.11) | (1.60) | (2.23) | 0.22 | (4.61) |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.02) | (0.02) | (0.01) | (0.04) | (0.02) | (0.04) | (0.05) |
Free Cash Flow per Share |
0.88 | 2.97 | (1.25) | (2.22) | (2.35) | (2.12) | (1.64) | (2.25) | 0.18 | (4.66) |
Cash per Share |
8.92 | 6.80 | 6.02 | 4.84 | 7.06 | 8.89 | 5.14 | 5.76 | 8.14 | 11.94 |
Shareholders Equity per Share |
9.67 | 10.97 | 5.93 | 4.40 | 6.48 | 8.13 | 3.09 | 5.03 | 6.82 | 13.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.67 | 10.97 | 5.93 | 4.40 | 6.48 | 8.13 | 3.09 | 5.03 | 6.82 | 13.47 |
Free Cash Flow |
56.08 | 182.80 | (70.84) | (108.93) | (108.97) | (72.95) | (42.49) | (50.43) | 3.21 | (30.32) |
Working Capital |
532.13 | 544.24 | 334.30 | 211.90 | 296.72 | 275.37 | 109.91 | 111.35 | 108.39 | 76.81 |
Capital Expenditures |
(1.59) | (1.35) | (0.61) | (0.79) | (1.10) | (0.47) | (0.97) | (0.49) | (0.67) | (0.35) |
Net Current Asset Value |
524.09 | 522.21 | 334.30 | 210.76 | 293.06 | 270.74 | 70.36 | 110.55 | 107.85 | 76.81 |
EV/EBIT |
0.00 | 7.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.03 | 0.00 | 0.01 | 0.03 | 0.04 | 0.02 | 4.19 | 0.02 | 0.03 | 0.00 |
Price to Operating Income |
0.00 | 9.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(1.13) | (1.87) | (1.05) | 1.80 | 2.56 | 1.89 | 1.15 | 0.85 | 1.24 | 0.77 |
Cash ROIC |
4.74% | 16.71% | (10.44%) | (24.05%) | (17.38%) | (12.46%) | (19.07%) | (20.89%) | 1.21% | (18.36%) |
Accounts Receivable Turnover |
0.56 | 4.96 | 11.99 | 33.73 | 13.71 | 6.24 | 0.04 | 9.66 | 9.89 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | 0.00 |
Average Receivables |
82.56 | 87.50 | 5.01 | 0.79 | 2.00 | 4.59 | 5.67 | 3.20 | 2.03 | 2.73 |
Average Payables |
3.48 | 1.20 | 2.24 | 3.10 | 4.15 | 4.93 | 5.41 | 4.01 | 1.21 | 1.21 |
Average Assets |
706.46 | 551.34 | 302.94 | 297.81 | 336.08 | 239.69 | 147.19 | 151.60 | 128.86 | 54.42 |
Average Common Equity |
645.00 | 505.99 | 276.14 | 257.81 | 289.81 | 179.79 | 96.24 | 116.57 | 104.09 | 30.08 |
Columns are period end dates